301301SZSE

2025 Annual Audit Report

✨ AI Summary

This audit report presents the financial statements of Yili Chuaning Biotechnology Co., Ltd. as of December 31, 2025. The audit concluded that the financial statements fairly represent the company's financial position and operational results in accordance with accounting standards. Key figures include total receivables of RMB 1,059,617,770.16 and revenue of RMB 461,626,960. The report identifies significant audit matters, including accounts receivable impairment and revenue recognition.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Table of Contents

  1. Audit Report……………………………………………………… Pages 1-6
  2. Financial Statements…………………………………………… Pages 7-14
    (1) Consolidated Balance Sheet…………………………………………… Page 7
    (2) Parent Company Balance Sheet………………………………………… Page 8
    (3) Consolidated Income Statement………………………………………… Page 9
    (4) Parent Company Income Statement………………………………………… Page 10
    (5) Consolidated Cash Flow Statement………………………………………… Page 11
    (6) Parent Company Cash Flow Statement………………………………………… Page 12
    (7) Consolidated Statement of Changes in Equity………………………………… Page 13
    (8) Parent Company Statement of Changes in Equity………………………………… Page 14
  3. Notes to Financial Statements………………………………………………… Pages 15-97
  4. Qualification Attachments …………………………………………………… Pages 98-102

Audit Report

Tianjian Audit [2026] No. 8-121
To all shareholders of Yili Chuaning Biotechnology Co., Ltd.:

  1. Audit Opinion
    We have audited the financial statements of Yili Chuaning Biotechnology Co., Ltd. (hereinafter referred to as Chuaning Biotechnology), including the consolidated and parent company balance sheets as of December 31, 2025, the consolidated and parent company income statements, consolidated and parent company cash flow statements, consolidated and parent company statements of changes in equity, and related notes to the financial statements. We believe that the attached financial statements are prepared in accordance with the provisions of enterprise accounting standards in all material respects and fairly present the financial position of Chuaning Biotechnology as of December 31, 2025, as well as the operational results and cash flows for the year 2025.

  2. Basis for Audit Opinion
    We conducted our audit in accordance with the auditing standards for certified public accountants in China. The section "Responsibilities of Certified Public Accountants for Auditing Financial Statements" further elaborates on our responsibilities under these standards. In accordance with the "Independence Standards for Certified Public Accountants No. 1 - Requirements for Independence in Financial Statement Audits and Reviews" and the Code of Ethics for Certified Public Accountants in China, we are independent of Chuaning Biotechnology and have fulfilled our other ethical responsibilities. We adhered to the independence requirements for auditing public interest entities. We believe that the audit evidence we obtained is sufficient and appropriate to provide a basis for our audit opinion.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.